Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Biomimetic Therapeutics, Inc. (BMTI) since 2010 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Biomimetic Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1138400.
Total stock buying since 2010: $8,945,183.
Total stock sales since 2010: $304,038.
Total stock option exercises since 2010: $1,974,120.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2013 | 0 | $0 | 1,381 | $11,187 | 484,680 | $1,575,235 |
| 2012 | 138,550 | $328,355 | 56,999 | $133,945 | 0 | $0 |
| 2011 | 14,900 | $116,828 | 37,271 | $136,585 | 7,500 | $59,700 |
| 2010 | 1,000,000 | $8,500,000 | 1,829 | $22,321 | 93,440 | $339,185 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2013-03 | 0 | $0 | 0 | $0 | 484,680 | $1,575,235 |
| 2013-01 | 0 | $0 | 1,381 | $11,187 | 0 | $0 |
| 2012-04 | 10,000 | $27,919 | 0 | $0 | 0 | $0 |
| 2012-03 | 128,550 | $300,436 | 56,999 | $133,945 | 0 | $0 |
| 2011-10 | 0 | $0 | 30,000 | $89,283 | 0 | $0 |
| 2011-06 | 0 | $0 | 6,500 | $37,030 | 0 | $0 |
| 2011-05 | 14,900 | $116,828 | 0 | $0 | 0 | $0 |
| 2011-04 | 0 | $0 | 0 | $0 | 7,500 | $59,700 |
| 2011-01 | 0 | $0 | 771 | $10,272 | 0 | $0 |
| 2010-12 | 0 | $0 | 0 | $0 | 63,750 | $231,412 |
| 2010-10 | 0 | $0 | 1,829 | $22,321 | 0 | $0 |
| 2010-09 | 0 | $0 | 0 | $0 | 9,720 | $35,283 |
| 2010-08 | 0 | $0 | 0 | $0 | 19,970 | $72,490 |
| 2010-07 | 1,000,000 | $8,500,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2013-03-01 | Pagano Russell P. (VP, Reg. & Clinical Affairs) | Option Ex | 70,000 | 2.08 | 145,600 |
| 2013-03-01 | Friedlaender Gary E (Director) | Option Ex | 38,736 | 4.21 | 163,272 |
| 2013-03-01 | Lynch Samuel Eugene (President and CEO) | Option Ex | 221,000 | 2.77 | 613,275 |
| 2013-03-01 | Murphy James G (Director) | Option Ex | 38,736 | 4.21 | 163,272 |
| 2013-03-01 | Papasan Larry W (Director) | Option Ex | 38,736 | 4.21 | 163,272 |
| 2013-03-01 | Federico Charles (Director) | Option Ex | 38,736 | 4.21 | 163,272 |
| 2013-03-01 | Watson Douglas G (Director) | Option Ex | 38,736 | 4.21 | 163,272 |
| 2013-01-22 | Pagano Russell P. (VP, Reg. & Clinical Affairs) | Sale | 1,381 | 8.10 | 11,187 |
| 2012-04-02 | Friedlaender Gary E (Director) | Buy | 10,000 | 2.79 | 27,919 |
| 2012-03-30 | Lynch Samuel Eugene (President and CEO) | Buy | 39,362 | 2.43 | 95,649 |
| 2012-03-29 | Pagano Russell P. (VP, Reg. & Clinical Affairs) | Sale | 3,438 | 2.36 | 8,127 |
| 2012-03-29 | Lynch Samuel Eugene (President and CEO) | Buy | 30,638 | 2.38 | 72,887 |
| 2012-03-28 | Douglas Earl Martin (General Counsel) | Sale | 47,461 | 2.35 | 111,533 |
| 2012-03-27 | Douglas Earl Martin (General Counsel) | Sale | 5,000 | 2.34 | 11,700 |
| 2012-03-27 | Papasan Larry W (Director) | Buy | 10,400 | 2.32 | 24,148 |
| 2012-03-26 | Douglas Earl Martin (General Counsel) | Sale | 1,100 | 2.35 | 2,585 |
| 2012-03-23 | Lynch Samuel Eugene (President and CEO) | Buy | 13,150 | 2.35 | 30,902 |
| 2012-03-20 | Bullock Lawrence E (Chief Financial Officer) | Buy | 17,670 | 2.20 | 38,874 |
| 2012-03-19 | Friedlaender Gary E (Director) | Buy | 15,000 | 2.19 | 32,850 |
| 2012-03-19 | Bullock Lawrence E (Chief Financial Officer) | Buy | 2,330 | 2.20 | 5,126 |
| 2011-10-14 | Douglas Earl Martin (General Counsel) | Sale | 3,000 | 3.06 | 9,165 |
| 2011-10-13 | Douglas Earl Martin (General Counsel) | Sale | 3,000 | 2.98 | 8,943 |
| 2011-10-12 | Douglas Earl Martin (General Counsel) | Sale | 3,000 | 2.99 | 8,970 |
| 2011-10-11 | Douglas Earl Martin (General Counsel) | Sale | 3,000 | 3.00 | 9,015 |
| 2011-10-10 | Douglas Earl Martin (General Counsel) | Sale | 3,000 | 2.97 | 8,910 |
| 2011-10-07 | Douglas Earl Martin (General Counsel) | Sale | 3,000 | 3.02 | 9,045 |
| 2011-10-06 | Douglas Earl Martin (General Counsel) | Sale | 3,000 | 2.99 | 8,964 |
| 2011-10-05 | Douglas Earl Martin (General Counsel) | Sale | 3,000 | 2.94 | 8,835 |
| 2011-10-04 | Douglas Earl Martin (General Counsel) | Sale | 3,000 | 2.89 | 8,679 |
| 2011-10-03 | Douglas Earl Martin (General Counsel) | Sale | 3,000 | 2.92 | 8,757 |
| 2011-06-10 | Papasan Larry W (Director) | Sale | 6,500 | 5.70 | 37,030 |
| 2011-05-19 | Pagano Russell P. (VP, Reg. & Clinical Affairs) | Buy | 1,900 | 7.95 | 15,103 |
| 2011-05-18 | Lynch Samuel Eugene (President and CEO) | Buy | 13,000 | 7.83 | 101,725 |
| 2011-04-25 | Friedlaender Gary E (Director) | Option Ex | 7,500 | 7.96 | 59,700 |
| 2011-01-25 | Pagano Russell P. (VP, Reg. & Clinical Affairs) | Sale | 771 | 13.32 | 10,272 |
| 2010-12-30 | Lynch Samuel Eugene (President and CEO) | Option Ex | 26,250 | 3.63 | 95,287 |
| 2010-12-03 | Bullock Lawrence E (Chief Financial Officer) | Option Ex | 37,500 | 3.63 | 136,125 |
| 2010-10-18 | Pagano Russell P. (VP, Reg. & Clinical Affairs) | Sale | 1,829 | 12.20 | 22,321 |
| 2010-09-07 | Murphy James G (Director) | Option Ex | 9,720 | 3.63 | 35,283 |
| 2010-08-23 | Friedlaender Gary E (Director) | Option Ex | 10,250 | 3.63 | 37,207 |
| 2010-08-23 | Papasan Larry W (Director) | Option Ex | 9,720 | 3.63 | 35,283 |
| 2010-07-15 | Novo A/s (10% Owner) | Buy | 1,000,000 | 8.50 | 8,500,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of BMTI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Biomimetic Therapeutics, Inc. (symbol BMTI, CIK number 1138400) see the Securities and Exchange Commission (SEC) website.